Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32 - ANTHEM–TIMI-32

Description:

The goal of the trial was to evaluate the safety and efficacy of a novel inhibitor of the tissue factor/factor VIIa complex, recombinant nematode anticoagulant protein c2 (NAPc2), among patients with non–ST-segment elevation acute coronary syndrome (NSTE ACS).